Top

Published in:

Open Access 05-10-2023 | Meningococcus | Review Article

Outer Membrane Vesicle Vaccine Platforms

Authors: Francesca Micoli, Roberto Adamo, Usman Nakakana

Published in: BioDrugs | Issue 1/2024

Abstract

Outer membrane vesicles (OMVs) are spontaneously released by many gram-negative bacteria during their growth and constitute an important virulence factor for bacteria, helping them to survive through harsh environmental conditions. Native OMVs, naturally-released from bacteria, are produced at a level too low for vaccine manufacturing, requiring chemical treatment (detergent-extracted) or genetic manipulation, resulting in generalized modules for membrane antigens (GMMAs). Over the years, the nature and properties of OMVs have made them a viable platform for vaccine development. There are a few licensed OMV vaccines mainly for the prevention of meningitis caused by Neisseria meningitidis serogroup B (MenB) and Haemophilus influenzae type b (Hib). There are several candidates in clinical development against other gram-negative organisms from which the OMVs are derived, but also against heterologous targets in which the OMVs are used as carriers (e.g. coronavirus disease 2019 [COVID-19]). The use of OMVs for targets other than those from which they are derived is a major advancement in OMV technology, improving its versatility by being able to deliver protein or polysaccharide antigens. Other advances include the range of genetic modifications that can be made to improve their safety, reduce reactogenicity, and increase immunogenicity and protective efficacy. However, significant challenges remain, such as identification of general tools for high-content surface expression of heterologous proteins on the OMV surface. Here, we outline the progress of OMV vaccines to date, particularly discussing licensed OMV-based vaccines and candidates in clinical development. Recent trends in preclinical research are described, mainly focused on genetic manipulation and chemical conjugation for the use of OMVs as carriers for heterologous protein and polysaccharide antigens. Remaining challenges with the use of OMVs and directions for future research are also discussed.

McBroom AJ, Johnson AP, Vemulapalli S, Kuehn MJ. Outer membrane vesicle production by Escherichia coli is independent of membrane instability. J Bacteriol. 2006;188(15):5385–92. https://doi.org/10.1128/jb.00498-06.CrossRefPubMedPubMedCentral

van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10(11):1689–706. https://doi.org/10.1002/biot.201400395.CrossRefPubMedPubMedCentral

Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74(1):81–94. https://doi.org/10.1128/mmbr.00031-09.CrossRefPubMedPubMedCentral

Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13(10):605–19. https://doi.org/10.1038/nrmicro3525.CrossRefPubMedPubMedCentral

Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13–24. https://doi.org/10.1038/s41579-018-0112-2.CrossRefPubMed

DeVoe IW, Gilchrist JE. Pili on meningococci from primary cultures of nasopharyngeal carriers and cerebrospinal fluid of patients with acute disease. J Exp Med. 1975;141(2):297–305. https://doi.org/10.1084/jem.141.2.297.CrossRefPubMed

Schooling SR, Beveridge TJ. Membrane vesicles: an overlooked component of the matrices of biofilms. J Bacteriol. 2006;188(16):5945–57. https://doi.org/10.1128/jb.00257-06.CrossRefPubMedPubMedCentral

Palsdottir H, Remis JP, Schaudinn C, O’Toole E, Lux R, Shi W, et al. Three-dimensional macromolecular organization of cryofixed Myxococcus xanthus biofilms as revealed by electron microscopic tomography. J Bacteriol. 2009;191(7):2077–82. https://doi.org/10.1128/jb.01333-08.CrossRefPubMedPubMedCentral

Kadurugamuwa JL, Beveridge TJ. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol. 1995;177(14):3998–4008. https://doi.org/10.1128/jb.177.14.3998-4008.1995.CrossRefPubMedPubMedCentral

10.

Rumbo C, Fernández-Moreira E, Merino M, Poza M, Mendez JA, Soares NC, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–90. https://doi.org/10.1128/aac.00929-10.CrossRefPubMedPubMedCentral

11.

Mancini F, Rossi O, Necchi F, Micoli F. OMV vaccines and the role of TLR agonists in immune response. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21124416.CrossRefPubMedPubMedCentral

12.

Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50: 101433. https://doi.org/10.1016/j.smim.2020.101433.CrossRefPubMed

13.

Piccioli D, Bartolini E, Micoli F. GMMA as a “plug and play” technology to tackle infectious disease to improve global health: context and perspectives for the future. Expert Rev Vaccines. 2022;21(2):163–72. https://doi.org/10.1080/14760584.2022.2009803.CrossRefPubMed

14.

Gnopo YMD, Watkins HC, Stevenson TC, DeLisa MP, Putnam D. Designer outer membrane vesicles as immunomodulatory systems—reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017;114:132–42. https://doi.org/10.1016/j.addr.2017.05.003.CrossRefPubMed

15.

Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–21. https://doi.org/10.1080/14760584.2018.1547637.CrossRefPubMed

16.

Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, Biolchi A, et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics. 2006;6(6):1856–66. https://doi.org/10.1002/pmic.200500164.CrossRefPubMed

17.

van de Waterbeemd B, Mommen GP, Pennings JL, Eppink MH, Wijffels RH, van der Pol LA, et al. Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. J Proteome Res. 2013;12(4):1898–908. https://doi.org/10.1021/pr301208g.CrossRefPubMed

18.

Bernadac A, Gavioli M, Lazzaroni JC, Raina S, Lloubes R. Escherichia coli tol-pal mutants form outer membrane vesicles. J Bacteriol. 1998;180(18):4872–8.CrossRefPubMedPubMedCentral

19.

Turner L, Praszkier J, Hutton ML, Steer D, Ramm G, Kaparakis-Liaskos M, et al. Increased outer membrane vesicle formation in a Helicobacter pylori tolB mutant. Helicobacter. 2015;20(4):269–83. https://doi.org/10.1111/hel.12196.CrossRefPubMed

20.

Mitra S, Sinha R, Mitobe J, Koley H. Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted Shigella boydii strain. Vaccine. 2016;34(15):1839–46. https://doi.org/10.1016/j.vaccine.2016.02.018.CrossRefPubMed

21.

Schwechheimer C, Rodriguez DL, Kuehn MJ. NlpI-mediated modulation of outer membrane vesicle production through peptidoglycan dynamics in Escherichia coli. MicrobiologyOpen. 2015;4(3):375–89. https://doi.org/10.1002/mbo3.244.CrossRefPubMedPubMedCentral

22.

Kulp AJ, Sun B, Ai T, Manning AJ, Orench-Rivera N, Schmid AK, et al. Genome-wide assessment of outer membrane vesicle production in Escherichia coli. PLoS ONE. 2015;10(9): e0139200. https://doi.org/10.1371/journal.pone.0139200.CrossRefPubMedPubMedCentral

23.

Roier S, Zingl FG, Cakar F, Durakovic S, Kohl P, Eichmann TO, et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun. 2016;7:10515. https://doi.org/10.1038/ncomms10515.CrossRefPubMedPubMedCentral

24.

Sonntag I, Schwarz H, Hirota Y, Henning U. Cell envelope and shape of Escherichia coli: multiple mutants missing the outer membrane lipoprotein and other major outer membrane proteins. J Bacteriol. 1978;136(1):280–5.CrossRefPubMedPubMedCentral

25.

Maharjan S, Saleem M, Feavers IM, Wheeler JX, Care R, Derrick JP. Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis. Microbiology (Reading, England). 2016;162(2):364–75. https://doi.org/10.1099/mic.0.000227.CrossRefPubMed

26.

Premjani V, Tilley D, Gruenheid S, Le Moual H, Samis JA. Enterohemorrhagic Escherichia coli OmpT regulates outer membrane vesicle biogenesis. FEMS Microbiol Lett. 2014;355(2):185–92. https://doi.org/10.1111/1574-6968.12463.CrossRefPubMed

27.

Elhenawy W, Bording-Jorgensen M, Valguarnera E, Haurat MF, Wine E, Feldman MF. LPS remodeling triggers formation of outer membrane vesicles in Salmonella. MBio. 2016. https://doi.org/10.1128/mBio.00940-16.CrossRefPubMedPubMedCentral

28.

McMahon KJ, Castelli ME, García Vescovi E, Feldman MF. Biogenesis of outer membrane vesicles in Serratia marcescens is thermoregulated and can be induced by activation of the Rcs phosphorelay system. J Bacteriol. 2012;194(12):3241–9. https://doi.org/10.1128/jb.00016-12.CrossRefPubMedPubMedCentral

29.

Sidik S, Kottwitz H, Benjamin J, Ryu J, Jarrar A, Garduno R, et al. A Shigella flexneri virulence plasmid encoded factor controls production of outer membrane vesicles. G3 (Bethesda). 2014;4(12):2493–503.CrossRefPubMedPubMedCentral

30.

Li Y, Wang Z, Chen J, Ernst RK, Wang X. Influence of lipid A acylation pattern on membrane permeability and innate immune stimulation. Mar Drugs. 2013;11(9):3197–208. https://doi.org/10.3390/md11093197.CrossRefPubMedPubMedCentral

31.

Han Y, Li Y, Chen J, Tan Y, Guan F, Wang X. Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharides. Mar Drugs. 2013;11(2):363–76. https://doi.org/10.3390/md11020363.CrossRefPubMedPubMedCentral

32.

Zariri A, van der Ley P. Biosynthetically engineered lipopolysaccharide as vaccine adjuvant. Expert Rev Vaccines. 2015;14(6):861–76. https://doi.org/10.1586/14760584.2015.1026808.CrossRefPubMed

33.

Rossi O, Pesce I, Giannelli C, Aprea S, Caboni M, Citiulo F, et al. Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants. J Biol Chem. 2014;289(36):24922–35. https://doi.org/10.1074/jbc.M114.566570.CrossRefPubMedPubMedCentral

34.

Rossi O, Caboni M, Negrea A, Necchi F, Alfini R, Micoli F, et al. Toll-like receptor activation by generalized modules for membrane antigens from lipid a mutants of Salmonella enterica Serovars Typhimurium and Enteritidis. Clin Vaccine Immunol. 2016;23(4):304–14. https://doi.org/10.1128/CVI.00023-16.CrossRefPubMedPubMedCentral

35.

Tondi S, Clemente B, Esposito C, Sammicheli C, Tavarini S, Martin LB, et al. Dissecting in vitro the activation of human immune response induced by Shigella sonnei GMMA. Front Cell Infect Microbiol. 2022;12: 767153. https://doi.org/10.3389/fcimb.2022.767153.CrossRefPubMedPubMedCentral

36.

van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001;69(10):5981–90. https://doi.org/10.1128/iai.69.10.5981-5990.2001.CrossRefPubMedPubMedCentral

37.

Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun. 2005;73(7):4070–80. https://doi.org/10.1128/iai.73.7.4070-4080.2005.CrossRefPubMedPubMedCentral

38.

Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, et al. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine. 2014;32(23):2688–95. https://doi.org/10.1016/j.vaccine.2014.03.068.CrossRefPubMed

39.

Gerke C, Colucci AM, Giannelli C, Sanzone S, Vitali CG, Sollai L, et al. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS ONE. 2015;10(8): e0134478. https://doi.org/10.1371/journal.pone.0134478.CrossRefPubMedPubMedCentral

40.

Gerritzen MJH, Salverda MLM, Martens DE, Wijffels RH, Stork M. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Vaccine. 2019;37(47):6978–86. https://doi.org/10.1016/j.vaccine.2019.01.076.CrossRefPubMed

41.

Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. https://doi.org/10.1016/j.vaccine.2018.12.061.CrossRefPubMed

42.

Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005–14. https://doi.org/10.4161/hv.29218.CrossRefPubMedPubMedCentral

43.

Bexsero summary of product characteristics. https://www.medicines.org.uk/emc/product/5168/smpc.

44.

Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. https://doi.org/10.1056/NEJMoa1901229.CrossRefPubMed

45.

Burton C, Best E, Broom M, Heffernan H, Briggs S, Webb R. Pediatric invasive meningococcal disease, Auckland, New Zealand (Aotearoa), 2004–2020. Emerg Infect Dis. 2023;29(4):686–95. https://doi.org/10.3201/eid2904.221397.CrossRefPubMedPubMedCentral

46.

Arnold R, Galloway Y, McNicholas A, O’Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–6. https://doi.org/10.1016/j.vaccine.2011.06.120.CrossRefPubMed

47.

Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–6. https://doi.org/10.1016/0140-6736(91)91961-s.CrossRefPubMed

48.

Caron F, du Châtelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–63. https://doi.org/10.1016/s1473-3099(11)70027-5.CrossRefPubMed

49.

Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207 (discussion 8–10).PubMed

50.

Sierra-González VG. Cuban meningococcal vaccine VA-MENGOC-BC: 30 years of use and future potential. MEDICC Rev. 2019;21(4):19–27. https://doi.org/10.37757/mr2019.V21.N4.4.CrossRefPubMed

51.

Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324(25):1767–72. https://doi.org/10.1056/nejm199106203242503.CrossRefPubMed

52.

Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992;121(2):187–94. https://doi.org/10.1016/s0022-3476(05)81186-2.CrossRefPubMed

53.

Recommendations for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria T, Pertussis, and Haemophilus b Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 42(RR-13). Publication date: 17 Sep 1993.

54.

Procomvax summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/procomvax-epar-product-information_en.pdf.

55.

Comvax summary of product characteristics. https://www.drugs.com/pro/comvax-vaccine.html.

56.

Vaxelis summary of product characteristics. https://www.medicines.org.uk/emc/product/12264/smpc.

57.

Gilsdorf JR. Hib vaccines: their impact on haemophilus influenzae type b disease. J Infect Dis. 2021;224(12 Suppl 2):S321–30. https://doi.org/10.1093/infdis/jiaa537.CrossRefPubMedPubMedCentral

58.

Schager AE, Dominguez-Medina CC, Necchi F, Micoli F, Goh YS, Goodall M, et al. IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal Salmonella develop at discordant rates. MBio. 2018. https://doi.org/10.1128/mBio.02379-17.CrossRefPubMedPubMedCentral

59.

De Benedetto G, Alfini R, Cescutti P, Caboni M, Lanzilao L, Necchi F, et al. Characterization of O-antigen delivered by generalized modules for membrane antigens (GMMA) vaccine candidates against nontyphoidal Salmonella. Vaccine. 2017;35(3):419–26. https://doi.org/10.1016/j.vaccine.2016.11.089.CrossRefPubMed

60.

Micoli F, Nakakana UN, Berlanda SF. Towards a four-component GMMA-based vaccine against Shigella. Vaccines. 2022. https://doi.org/10.3390/vaccines10020328.CrossRefPubMedPubMedCentral

61.

Micoli F, Rondini S, Alfini R, Lanzilao L, Necchi F, Negrea A, et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. Proc Natl Acad Sci USA. 2018;41(115):10428–33.CrossRef

62.

Micoli F, Rossi O, Conti V, Launay O, Sciré AS, Aruta MG, et al. Antibodies elicited by the Shigella sonnei GMMA vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension. Front Immunol. 2021;12: 671325. https://doi.org/10.3389/fimmu.2021.671325.CrossRefPubMedPubMedCentral

63.

Obiero CW, Ndiaye AGW, Scire AS, Kaunyangi BM, Marchetti E, Gone AM, et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front Immunol. 2017;8:1884. https://doi.org/10.3389/fimmu.2017.01884.CrossRefPubMedPubMedCentral

64.

Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Scire AS, et al. Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine. 2017;22:164–72. https://doi.org/10.1016/j.ebiom.2017.07.013.CrossRefPubMedPubMedCentral

65.

Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, et al. Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: exploratory analysis of a Phase 2a randomized study. Front Immunol. 2022;13: 971866. https://doi.org/10.3389/fimmu.2022.971866.CrossRefPubMedPubMedCentral

66.

Launay O, Ndiaye AGW, Conti V, Loulergue P, Scire AS, Landre AM, et al. Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results from a phase 1 clinical trial. Front Immunol. 2019;10:335. https://doi.org/10.3389/fimmu.2019.00335.CrossRefPubMedPubMedCentral

67.

Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. https://doi.org/10.1016/s0140-6736(17)31449-6.CrossRefPubMed

68.

Whelan J, Kløvstad H, Haugen IL, Holle MR, Storsaeter J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis. 2016;22(6):1137–9. https://doi.org/10.3201/eid2206.151093.CrossRefPubMedPubMedCentral

69.

Azze RFO. A meningococcal B vaccine induces cross-protection against gonorrhea. Clin Exp Vaccine Res. 2019;8(2):110–5. https://doi.org/10.7774/cevr.2019.8.2.110.CrossRefPubMedPubMedCentral

70.

Bishop AL, Schild S, Patimalla B, Klein B, Camilli A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun. 2010;78(10):4402–20. https://doi.org/10.1128/iai.00398-10.CrossRefPubMedPubMedCentral

71.

Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun. 2008;76(10):4554–63. https://doi.org/10.1128/iai.00532-08.CrossRefPubMedPubMedCentral

72.

Li B, Xu Y, Xu T, Guo Z, Xu Q, Li Y, et al. Disruption of sncRNA improves the protective efficacy of outer membrane vesicles against Helicobacter pylori infection in a mouse model. Infect Immun. 2022;90(8): e0026722. https://doi.org/10.1128/iai.00267-22.CrossRefPubMed

73.

Liu Q, Liu Q, Yi J, Liang K, Hu B, Zhang X, et al. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Sci Rep. 2016;6:34776. https://doi.org/10.1038/srep34776.CrossRefPubMedPubMedCentral

74.

Chen Y, Jie K, Li B, Yu H, Ruan H, Wu J, et al. Immunization with outer membrane vesicles derived from major outer membrane protein-deficient salmonella typhimurium mutants for cross protection against Salmonella Enteritidis and avian pathogenic Escherichia coli O78 infection in chickens. Front Microbiol. 2020;11: 588952. https://doi.org/10.3389/fmicb.2020.588952.CrossRefPubMedPubMedCentral

75.

Bartolini E, Ianni E, Frigimelica E, Petracca R, Galli G, Berlanda Scorza F, et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J Extracell Vesicles. 2013. https://doi.org/10.3402/jev.v2i0.20181.CrossRefPubMedPubMedCentral

76.

Fantappiè L, de Santis M, Chiarot E, Carboni F, Bensi G, Jousson O, et al. Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracellular Vesicles. 2014. https://doi.org/10.3402/jev.v3.24015.CrossRef

77.

Kesty NC, Kuehn MJ. Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem. 2004;279(3):2069–76. https://doi.org/10.1074/jbc.M307628200.CrossRefPubMed

78.

Kim SH, Kim KS, Lee SR, Kim E, Kim MS, Lee EY, et al. Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. Biochem Biophys Acta. 2009;1788(10):2150–9. https://doi.org/10.1016/j.bbamem.2009.08.001.CrossRefPubMed

79.

Muralinath M, Kuehn MJ, Roland KL, Curtiss R 3rd. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun. 2011;79(2):887–94. https://doi.org/10.1128/iai.00950-10.CrossRefPubMed

80.

Schild S, Nelson EJ, Bishop AL, Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun. 2009;77(1):472–84. https://doi.org/10.1128/iai.01139-08.CrossRefPubMed

81.

Salverda ML, Meinderts SM, Hamstra HJ, Wagemakers A, Hovius JW, van der Ark A, et al. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles. Vaccine. 2016;34(8):1025–33. https://doi.org/10.1016/j.vaccine.2016.01.019.CrossRefPubMed

82.

Necchi F, Stefanetti G, Alfini R, Palmieri E, Carducci M, Di Benedetto R, et al. Neisseria meningitidis factor H binding protein surface exposure on Salmonella typhimurium GMMA Is critical to induce an effective immune response against both diseases. Pathogens (Basel, Switzerland). 2021. https://doi.org/10.3390/pathogens10060726.

83.

Alfini R, Brunelli B, Bartolini E, Carducci M, Luzzi E, Ferlicca F, et al. Investigating the role of antigen orientation on the immune response elicited by Neisseria meningitidis factor H binding protein on GMMA. Vaccines. 2022. https://doi.org/10.3390/vaccines10081182.CrossRefPubMedPubMedCentral

84.

Georgiou G, Segatori L. Preparative expression of secreted proteins in bacteria: status report and future prospects. Curr Opin Biotechnol. 2005;16(5):538–45. https://doi.org/10.1016/j.copbio.2005.07.008.CrossRefPubMed

85.

Jong WS, Daleke-Schermerhorn MH, Vikström D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, et al. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Fact. 2014;13:162. https://doi.org/10.1186/s12934-014-0162-8.CrossRefPubMedPubMedCentral

86.

Daleke-Schermerhorn MH, Felix T, Soprova Z, Ten Hagen-Jongman CM, Vikstrom D, Majlessi L, et al. Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach. Appl Environ Microbiol. 2014;80(18):5854–65. https://doi.org/10.1128/aem.01941-14.CrossRefPubMedPubMedCentral

87.

Kuipers K, Daleke-Schermerhorn MH, Jong WS, ten Hagen-Jongman CM, van Opzeeland F, Simonetti E, et al. Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization. Vaccine. 2015;33(17):2022–9. https://doi.org/10.1016/j.vaccine.2015.03.010.CrossRefPubMed

88.

Kim JY, Doody AM, Chen DJ, Cremona GH, Shuler ML, Putnam D, et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol. 2008;380(1):51–66. https://doi.org/10.1016/j.jmb.2008.03.076.CrossRefPubMedPubMedCentral

89.

Chen DJ, Osterrieder N, Metzger SM, Buckles E, Doody AM, DeLisa MP, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci USA. 2010;107(7):3099–104. https://doi.org/10.1073/pnas.0805532107.CrossRefPubMedPubMedCentral

90.

Huang W, Wang S, Yao Y, Xia Y, Yang X, Li K, et al. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep. 2016;6:37242. https://doi.org/10.1038/srep37242.CrossRefPubMedPubMedCentral

91.

van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol. 2021;12: 781280. https://doi.org/10.3389/fimmu.2021.781280.CrossRefPubMedPubMedCentral

92.

Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, et al. Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine. Res Square. 2023. https://doi.org/10.21203/rs.3.rs-2788726/v1.CrossRef

93.

Shehata MM, Mostafa A, Teubner L, Mahmoud SH, Kandeil A, Elshesheny R, et al. Bacterial outer membrane vesicles (OMVs)-based dual vaccine for Influenza A H1N1 virus and MERS-CoV. Vaccines. 2019. https://doi.org/10.3390/vaccines7020046.CrossRefPubMedPubMedCentral

94.

Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA. 2012;109(12):E690–7. https://doi.org/10.1073/pnas.1115485109.CrossRefPubMedPubMedCentral

95.

Alves NJ, Turner KB, Daniele MA, Oh E, Medintz IL, Walper SA. Bacterial nanobioreactors-directing enzyme packaging into bacterial outer membrane vesicles. ACS Appl Mater Interfaces. 2015;7(44):24963–72. https://doi.org/10.1021/acsami.5b08811.CrossRefPubMed

96.

van den Berg van Saparoea HB, Houben D, Kuijl C, Luirink J, Jong WSP. Combining protein ligation systems to expand the functionality of semi-synthetic outer membrane vesicle nanoparticles. Front Microbiol. 2020;11:890. https://doi.org/10.3389/fmicb.2020.00890.

97.

Jiang L, Driedonks TAP, Jong WSP, Dhakal S, Bart van den Berg van Saparoea H, Sitaras I, et al. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. J Extracellular Vesicles. 2022;11(3):e12192. https://doi.org/10.1002/jev2.12192.

98.

Weyant KB, Oloyede A, Pal S, Liao J, Jesus MR, Jaroentomeechai T, et al. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens. Nat Commun. 2023;14(1):464. https://doi.org/10.1038/s41467-023-36101-2.CrossRefPubMedPubMedCentral

99.

Di Benedetto R, Alfini R, Carducci M, Aruta MG, Lanzilao L, Acquaviva A, et al. Novel simple conjugation chemistries for decoration of GMMA with heterologous antigens. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms221910180.CrossRefPubMedPubMedCentral

100.

Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, et al. GMMA is a versatile platform to design effective multivalent combination vaccines. Vaccines. 2020. https://doi.org/10.3390/vaccines8030540.CrossRefPubMedPubMedCentral

101.

Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, et al. Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230. NPJ Vaccines. 2019;4:24. https://doi.org/10.1038/s41541-019-0121-9.CrossRefPubMedPubMedCentral

102.

Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA. 2006;103(48):18243–8. https://doi.org/10.1073/pnas.0608545103.CrossRefPubMedPubMedCentral

103.

Hu K, Palmieri E, Samnuan K, Ricchetti B, Oldrini D, McKay PF, et al. Generalized modules for membrane antigens (GMMA), an outer membrane vesicle-based vaccine platform, for efficient viral antigen delivery. J Extracellular Vesicles. 2022;11(11): e12247. https://doi.org/10.1002/jev2.12247.CrossRef

104.

Donnelly JJ, Deck RR, Liu MA. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol. 1990;145(9):3071–9.CrossRefPubMed

105.

Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol. 2004;172(4):2431–8. https://doi.org/10.4049/jimmunol.172.4.2431.CrossRefPubMed

106.

Adamo R, Feron C. Conjugated haemophilus influenzae vaccine using Bordetella outer membrane vesicle. Immunogenic conjugates. WIPO Patent Application WO2020043874. Application no. PCT/EP2019/073195 (2019).

107.

Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, et al. Generalized modules for membrane antigens as carrier for polysaccharides: impact of sugar length, density, and attachment site on the immune response elicited in animal models. Front Immunol. 2021;12: 719315. https://doi.org/10.3389/fimmu.2021.719315.CrossRefPubMedPubMedCentral

108.

Raso MM, Gasperini G, Alfini R, Schiavo F, Aruta MG, Carducci M, et al. GMMA and glycoconjugate approaches compared in mice for the development of a vaccine against Shigella flexneri serotype 6. Vaccines. 2020. https://doi.org/10.3390/vaccines8020160.CrossRefPubMedPubMedCentral

109.

Palmieri E, Kis Z, Ozanne J, Di Benedetto R, Ricchetti B, Massai L, et al. GMMA as an alternative carrier for a glycoconjugate vaccine against Group A Streptococcus. Vaccines. 2022. https://doi.org/10.3390/vaccines10071034.CrossRefPubMedPubMedCentral

110.

Gasperini G, Alfini R, Arato V, Mancini F, Aruta MG, Kanvatirth P, et al. Salmonella paratyphi a outer membrane vesicles displaying vi polysaccharide as a multivalent vaccine against enteric fever. Infect Immunity. 2021. https://doi.org/10.1128/iai.00699-20.CrossRef

111.

Piccioli D, Alfini R, Monaci V, Arato V, Carducci M, Aruta MG, et al. Antigen presentation by follicular dendritic cells to cognate b cells is pivotal for generalised modules for membrane antigens (GMMA) immunogenicity. Vaccine. 2022;40(44):6305–14. https://doi.org/10.1016/j.vaccine.2022.09.034.CrossRefPubMed

112.

Valguarnera E, Feldman MF. Glycoengineered outer membrane vesicles as a platform for vaccine development. Meth Enzymol. 2017;597:285–310. https://doi.org/10.1016/bs.mie.2017.06.032.CrossRef

113.

Chen L, Valentine JL, Huang C-J, Endicott CE, Moeller TD, Rasmussen JA, et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proceed Natl Acad Sci USA. 2016:E3609–E18. https://doi.org/10.1073/pnas.1518311113.

114.

Price NL, Goyette-Desjardins G, Nothaft H, Valguarnera E, Szymanski CM, Segura M, et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci Rep. 2016;6:24931. https://doi.org/10.1038/srep24931.CrossRefPubMedPubMedCentral

115.

Stevenson TC, Cywes-Bentley C, Moeller TD, Weyant KB, Putnam D, Chang Y-F, et al. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc Natl Acad Sci USA. 2018;115(8):E3106–15.PubMedPubMedCentral

116.

Tian H, Li B, Xu T, Yu H, Chen J, Yu H, et al. Outer membrane vesicles derived from salmonella enterica serotype typhimurium can deliver Shigella flexneri 2a O-polysaccharide antigen to prevent Shigella flexneri 2a infection in mice. Appl Environ Microbiol. 2021;87(19): e0096821. https://doi.org/10.1128/aem.00968-21.CrossRefPubMed

Title: Outer Membrane Vesicle Vaccine Platforms
Authors: Francesca Micoli
Roberto Adamo
Usman Nakakana
Publication date: 05-10-2023
Publisher: Springer International Publishing
Keyword: Meningococcus
Published in: BioDrugs / Issue 1/2024
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-023-00627-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Outer Membrane Vesicle Vaccine Platforms

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

Acknowledgement to Referees

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis

Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study